Exchange: NASDAQ·Updated 07:46 PM EDT
News
all
press releases
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
More News
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.
Zacks
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.
Zacks
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +200.00% and +4.81%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17...
Business Wire
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.
Zacks
ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
Zoetis heads into Q2 earnings with companion animal products and international growth in focus as U.S. competition and Librela concerns weigh.
Zacks
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.
Zacks
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the companys website, acadia.com, under the...
Business Wire
HRMY or ACAD: Which Is the Better Value Stock Right Now?
HRMY vs. ACAD: Which Stock Is the Better Value Option?
Zacks

Advertisement|Remove ads.